Polycythemia Vera Clinical Trial
Official title:
Investigator-Initiated Trial of the LSD1 Inhibitor IMG-7289 for the Treatment of Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) That Have Failed at Least One Standard Therapy
Verified date | June 2024 |
Source | University of Miami |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.
Status | Active, not recruiting |
Enrollment | 4 |
Est. completion date | October 31, 2025 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18 years. 2. Diagnosis of Essential Thrombocythemia or Polycythemia Vera per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Arber et al., 2016). 3. Patients that have failed at least one standard therapy (failure is the equivalent of inadequate response or intolerance). 4. Platelet count >400 x 10^9/L pre-dose Day 1for patients with essential thrombocytopenia. 5. Platelet count >150 x 10^9/L pre-dose Day 1 for patients with polycythemia vera. 6. Peripheral blast count < 10% pre-dose Day 1. 7. Absolute neutrophil count (ANC) = 0.5 x 10^9/L pre-dose Day 1. 8. Fibrosis score = grade 2, as per a slightly modified version (Arber et al., 2016) of the European Consensus Criteria for Grading Myelofibrosis, (Thiele et al., 2005). 9. Life expectancy > 36 weeks. 10. Able to swallow capsules. 11. Amenable to blood draws, spleen size determination, bone marrow evaluations, and peripheral blood sampling during the study. 12. Must have discontinued prior therapy for condition under study for 2 weeks (4 weeks for interferon) prior to study drug initiation. 13. Agrees to use an approved method of contraception from Screening until 28 days after last administration of the study drug. 14. If male, agrees not to donate sperm or father a child for at least one month after the last dose of the study medication. Exclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) questionnaire score of 3 or greater. 2. Currently pregnant, planning on being pregnant in the following 6 months or currently breastfeeding. 3. Currently residing outside the United States. 4. History of splenectomy. 5. Unresolved treatment related toxicities from prior therapies (unless resolved to = Grade 1). 6. Uncontrolled active infection. 7. Known positive for HIV if not well-controlled (i.e., undetectable viral load), or infectious hepatitis, type A, B or C. 8. Current use of monoamine oxidase A and B inhibitors (MAOIs). 9. Evidence at the time of screening of increased risk of bleeding, including any of the following: - Activated partial thromboplastin time (aPTT) > 1.3 x the upper limit of normal - International normalized ratio (INR) >1.3 x the local upper limit of normal - History of severe thrombocytopenia or platelet dysfunction unrelated to a myeloproliferative disorder or its treatment - Known bleeding disorder (e.g., dysfibrinogenaemia, factor IX deficiency, haemophilia, Von Willebrand's disorder, Disseminated Intravascular Coagulation [DIC], fibrinogen deficiency, or other clotting factor deficiency) 10. Evidence at the time of Screening of significant renal or hepatic insufficiency (unless due to haemolysis, or leukaemic infiltration) as defined by any of the following local lab parameters: 1. Calculated glomerular filtration rate (GFR; using the Cockcroft-Gault equation) < 40 mL/min or serum creatinine > 1.5 x the local upper limit of normal 2. Aspartate transaminase (AST) or alanine aminotransferase (ALT) = 2 x the local upper limit of normal 11. Current use of a prohibited medication (e.g., romiplostim) or expected to require any of these medications during treatment with the investigational drug. 12. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to IMG-7289 or LSD1 inhibitors (i.e., monoamine oxidase inhibitors; MAOIs) that contraindicates their participation. 13. Patients with impaired decision-making capacity. |
Country | Name | City | State |
---|---|---|---|
United States | University of Miami | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
Terrence J Bradley, MD | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hematologic Response Rates | As evaluated by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) response criteria. | 24 Weeks | |
Secondary | Incidence of Treatment-Related Toxicity | As evaluated by the treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. | Up to 3 Years | |
Secondary | Change in Total Symptom Score (TSS) as Measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) | As measured using the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) that includes 14 disease related symptoms each scored from 0 (absent) to 10 (worst imaginable). | Baseline, Up to 3 Years | |
Secondary | Change in Mutational Allele Burden | Evaluated via Next Generation Sequencing (NGS) molecular profiling from serum blood sample. | Baseline, Up to 3 Years | |
Secondary | Change in Spleen Size in Centimeters | Measured via physical examination and radiologic imaging measurement. | Baseline, Up to 3 Years | |
Secondary | Change in Fibrosis Score | Assessed using a slightly modified version of European Consensus Criteria for Grading Myelofibrosis from bone marrow/aspirate sample, as presented in Thiele et al, 2005. Myelofibrosis (MF) scores are graded on a four-point scale, from MF-0 to MF-3, grading the reticulin and collagen content of bone marrow, with MF-0 being the lowest and MF-3 the highest. | Baseline, Up to 3 Years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05558696 -
A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)
|
Phase 2 | |
Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
Completed |
NCT02912884 -
Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
|
||
Recruiting |
NCT02897297 -
Myeloproliferative Neoplastic Diseases Observatory From Brest
|
||
Completed |
NCT01949805 -
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
|
Phase 3 | |
Completed |
NCT00666549 -
Research Tissue Bank
|
||
Completed |
NCT00241241 -
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
|
Phase 2 | |
Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05485948 -
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
|
Phase 2 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT01243944 -
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
|
Phase 3 | |
Recruiting |
NCT05481151 -
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
|
Phase 3 | |
Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT04116502 -
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
|
Phase 3 | |
Completed |
NCT01901432 -
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05566535 -
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
|
||
Active, not recruiting |
NCT04057040 -
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
|
Phase 2 | |
Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
Completed |
NCT01981850 -
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
|
Phase 2 | |
Active, not recruiting |
NCT00588991 -
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
|
Phase 1 |